delamanid delamanid delamanid, sold under the brand name deltyba, is a medication used to treat tuberculosis. specifically it is used, along with other antituberculosis medications, for active multidrug-resistant tuberculosis. it is taken by mouth. delamanidclinical datatrade namesdeltybaother namesopc-67683ahfs/drugs.comuk drug informationlicense data eu ema: by inn routes ofadministrationby mouth (film-coated tablets)atc codej04ak06 (who) legal statuslegal status uk: pom (prescription only) eu: rx-only in general: ℞ (prescription only) pharmacokinetic dataprotein binding≥99.5%metabolismin plasma by albumin, in liverby cyp3a4 (to a lesser extent)elimination half-life30–38 hoursexcretionnot excreted in urineidentifiers iupac name (2r)-2-methyl-6-nitro-2--1-piperidinyl}phenoxy)methyl]-2,3-dihydroimidazo oxazole cas number681492-22-8pubchem cid6480466drugbankdb11637chemspider4981055unii8oot6m1pc7keggd09785chebichebi:134742chemblchembl218650comptox dashboard (epa)dtxsid60218326 chemical and physical dataformulac25h25f3n4o6molar mass534.492 g·mol−13d model (jsmol)interactive image smiles fc(f)(f)oc5ccc(oc4ccn(c3ccc(oc2(oc1nc(cn1c2)()=o)c)cc3)cc4)cc5 inchi inchi=1s/c25h25f3n4o6/c1-24(15-31-14-22(32(33)34)29-23(31)38-24)16-35-18-4-2-17(3-5-18)30-12-10-20(11-13-30)36-19-6-8-21(9-7-19)37-25(26,27)28/h2-9,14,20h,10-13,15-16h2,1h3/t24-/m1/s1key:xdaoltsrnuspph-xmmpixpasa-n common side effects include headache, dizziness, and nausea. other side effects include qt prolongation. it has not been studied in pregnancy as of 2016. delamanid works by blocking the manufacture of mycolic acids thus destabilising the bacterial cell wall. it is in the nitroimidazole class of medications. delamanid was approved for medical use in 2014 in europe, japan, and south korea. it is on the world health organization's list of essential medicines. as of 2016 the stop tb partnership had an agreement to get the medication for us$1,700 per six month for use in more than 100 countries. medical uses delamanid is used, along with other antituberculosis medications, for active multidrug-resistant tuberculosis. adverse effects common side effects include headache, dizziness, and nausea. other side effects include qt prolongation. it has not been studied in pregnancy as of 2016. interactions delamanid is metabolised by the liver enzyme cyp3a4; therefore strong inducers of this enzyme can reduce its effectiveness. history in phase ii clinical trials, the drug was used in combination with standard treatments, such as four or five of the drugs ethambutol, isoniazid, pyrazinamide, rifampicin, aminoglycoside antibiotics, and quinolones. healing rates (measured as sputum culture conversion) were significantly better in patients who additionally took delamanid. the european medicines agency (ema) recommended conditional marketing authorization for delamanid in adults with multidrug-resistant pulmonary tuberculosis without other treatment options because of resistance or tolerability. the ema considered the data show that the benefits of delamanid outweigh the risks, but that additional studies were needed on the long-term effectiveness. society and culture the medication was not readily available globally as of 2015. it was believed that pricing will be similar to bedaquiline, which for six months is approximately us$900 in low income countries, us$3,000 in middle income countries, and us$30,000 in high income countries. as of 2016 the stop tb partnership had an agreement to get the medication for us$1,700 per six month.